Day 1 | Day 2 | Download Brochure | Speaker Bios
MONDAY, MAY 5
RECOMMENDED PRE-CONFERENCE SHORT COURSES*
Antibody Humanization via One Hot Homology Model (Hands-On) Workshop - View Detailed Agenda
In silico Immunogenicity Predictions (Hands-On) Workshop - View Detailed Agenda
*Separate registration required
7:00 am Registration and Morning Coffee
» Plenary Keynote Session
8:30 Chairperson’s Opening Plenary Remarks
Kristi Sarno, Chair, Greater Boston Chapter, Women in Bio; Director, Business Development, Pfenex, Inc.
8:40 Harnessing the Patient’s Immune System to Combat Cancer
Bahija Jallal, Ph.D., Executive Vice President, MedImmune
With recent FDA approvals, modulation of the immune system is now a clinically validated approach in the treatment of some cancers. At MedImmune, the Oncology Department is developing assets and expertise in Immune Mediated Therapy of Cancer (IMT-C). The challenges from a drug development perspective are multi-fold. The talk will focus on the relevance of preclinical models and translational science to address key issues, including dose selection and rationale combinations.
9:25 Building Regeneron’s Pipeline: From Trap Technology to the VelocImmune Platform to Veloci-Next
George D. Yancopoulos, M.D., Ph.D., President, Regeneron Laboratories; CSO, Regeneron Pharmaceuticals, Inc.
George D. Yancopoulos, M.D., Ph.D., who is the Founding Scientist, President, Research Laboratories and Chief Scientific Officer of Regeneron Pharmaceuticals, one of the world’s top biotechnology companies, will discuss how he and his colleagues exploited a commitment to science and technology to start the company, withstand years of challenges and failures, and emerge with a pipeline of promising technologies and novel/biologics that are beginning to bring hope to countless patients and their families.
10:10 Grand Opening Coffee Break in the Exhibit Hall with Poster Viewing
11:05 Chairperson's Remarks
» KEYNOTE PRESENTATION:
11:10 Construct and Expression Optimization of the G Protein-Coupled Neurotensin Receptor for Structure Determination
Reinhard Grisshammer, Ph.D., Biotechnology Core Laboratory, National Institute of Diabetes and Digestive and Kidney Diseases
In the past few years, we started to see an explosion in the field of GPCR structure determination with structures of more than 20 unique receptors now deposited in the Protein Data Bank. This exciting progress required a tremendous amount of methods development contributed by many laboratories. I will discuss our approaches that led to successful overproduction, crystallization and structure determination of the neurotensin receptor NTS1 bound to its peptide agonist.
11:40 Artificial Environments and Quality Modulation of Cell-Free Expressed GPCRs: Case Studies of the Human Endothelin and Gonadotropin Releasing Hormone Receptors
Erika Orbán, Ph.D., Postdoctoral Fellow, Institute of Biophysical Chemistry, Goethe University
Protocol development and defining the optimal biosynthetic environment for functionally folded and stable membrane protein samples is a complex issue and requires systematic evaluation of numerous additives. We present case studies for the optimization of cell-free expression protocols of the human Endothelin and Gonadotropin Releasing Hormone receptors. The co- and post-translational solubilization of the synthesized GPCRs in several hydrophobic environments including nanodiscs, amphipols and surfactants was analyzed.
12:10 pm Discovery of MAbs Against Difficult GPCRs, Ion Channels, and Transporters
Benjamin Doranz, Ph.D., CSO, Integral Molecular, Inc.
To enable the isolation, characterization, and engineering of MAbs against challenging membrane protein targets, Integral Molecular has developed the MPS Discovery Engine™ platform, encompassing Lipoparticles for concentrating native membrane proteins and Shotgun Mutagenesis for membrane protein engineering and epitope mapping. Using the MPS platform, we have generated inhibitory MAbs against the ion channel P2X3 for treating neuropathic and inflammatory pain, and have ongoing discovery programs against additional GPCR, ion channel, and transporter targets.
12:40 Luncheon Presentations (Sponsorship Opportunities Available) or Lunch on Your Own
1:40 Session Break
2:00 Chairperson's Remarks
2:05 TAPBOOST Technology: Novel Technology to Enhance the Production of Hard-to-Produce Therapeutic Recombinant Proteins
Akinori Hishiya, Ph.D., Director, Biology, Boston Strategics Corporation
A proprietary protein (TAPBOOSTER) is expressed together with the therapeutic protein. The TAPBOOSTER protein binds to targeted proteins and enhances its production specifically. TAPBOOSTER has successfully enhanced the production of many therapeutic recombinant proteins including monoclonal antibodies and Fc fusion proteins. The technology is particularly effective in enhancing the production of proteins where incorrect folding may result.
2:35 Rapid Screening of Membrane Protein Expression in Transiently Transfected Insect Cells
Hao Chen, Ph.D., Sr. Scientist, Protein Technologies, Amgen, Inc.
Membrane proteins play critical roles in many biological processes and constitute the majority of all drug targets. However, producing correctly folded and stable membrane proteins is often difficult and requires intensive protein engineering and optimization. Here, we present a rapid method for screening membrane protein expression in insect cells.
3:05 Cell-Free Systems: Functional Modules for Synthetic and Chemical Biology
Marlitt Stech, MSc, Cell-Free Protein Synthesis, Fraunhofer IBMT-Potsdam
Here we present recent advances for the synthesis of glycoproteins, proteins containing disulfide bridges, membrane proteins, and fluorescently labeled proteins. The basis for the expression of these difficult-to-express target proteins is a translationally active cell extract which can be prepared from eukaryotic cell lines such as Spodoptera frugiperda 21 (Sf21) and Chinese hamster ovary (CHO) cells.
3:35 High-Yield Membrane Protein Expression from E. coli Using an Engineered Outer Membrane Protein F Fusion
Bryan Berger, Ph.D., Head, Berger Lab; Assistant Professor, Chemical Engineering, Lehigh University
An Escherichia coli-based membrane protein overexpression system utilizing an engineered bacterial outer membrane protein F (pOmpF) fusion has been developed. Full-length human receptor activity-modifying protein 1 (RAMP1) was expressed using pOmpF, solubilized in FC15 and purified to homogeneity. Our approach provides a useful, complementary approach to achieve high-yield, full-length membrane protein overexpression for biophysical studies.
4:05 Refreshment Break in the Exhibit Hall with Poster Viewing
4:45 Problem Solving Breakout Discussions
Never mind the PTMs, What about the folding?
Moderator: David O’Connell, Ph.D., School of Biomolecular and Biomedical Research, University College, Dublin; Conway Institute of Biomolecular & Biomedical Research, UCD, Dublin
- Does overexpression of mammalian proteins in lower eukaryotes really fit the bill
- Where heterodimers are concerned, how can we be sure of correct folding to promote complex formation
- Apart from posttranslational modifications how confident can we be of structural integrity
- What are the key assays to determine proper folding
- What assays can we develop in the discovery lab e.g, binding analysis, protein-protein interaction
- When is overexpression just too much?
Overcoming Problems with Membrane Protein Characterization
Moderator: Bryan Berger, Ph.D., Head, Berger Lab; Assistant Professor, Chemical Engineering, Lehigh University
Effects of Preliminary Data on Protein Expression Strategy
Moderator: Brian Chiswell, Ph.D., Owner and Founder, Dimesions BioSciences
- Which data is most influential in deciding to proceed?
- Which data brings the project to a halt?
- When should optimization begin?
- Should multiple constructs be carried through entire characterization and scale-up?
Recombinant Expression of Toxins and Peptides
Moderator: Jacques Dumas, Ph.D., Head of Protein Production Vitry, Biologics SCP, Vitry Research Center, sanofi
- Expression systems
- Peptide size limitations
- Mammalian versus microbial
- Is recombinant expression competitive to synthesis
Membrane Protein Expression in Insect Cells
Moderator: Hao Chen, Ph.D., Scientist, Molecular Structure, Amgen
- Advantages/disadvantages of using insect cells as the expression host
- Expression vectors and construct design
- New developments
5:45 Welcome Reception in the Exhibit Hall with Poster Viewing
6:45 End of Day
Day 1 | Day 2 | Download Brochure | Speaker Bios